Defining a mutational signature for endometrial cancer screening and early detection.


Program Against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain. Electronic address: [Email]


The current availability of genomic information represents an opportunity to develop new strategies for early detection of cancer. New molecular tests for endometrial cancer may improve performance and failure rates of histological aspirate-based diagnosis, and provide promising perspectives for a potential screening scenario. However, the selection of relevant biomarkers to develop efficient strategies can be a challenge.


Algorithm,Biomarkers,Early detection,Endometrial cancer,Genomics,Screening,

OUR Recent Articles